Tempus AI announced the national launch of its FDA-approved, NGS-based in vitro diagnostic device, xT CDx. This test is now available for all ordering clinicians nationwide, marking a significant expansion of Tempus's diagnostic offerings.
The xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. It leverages a normal-matched approach for more accurate identification of cancer-driving somatic variants.
All orders for tumor + normal match tests, traditionally run on the company’s signature xT assay, will now be run as xT CDx with no changes to the current ordering workflow. Clinicians can further enhance molecular insights by adding other Tempus tests and algorithmic solutions, promoting a streamlined, one-stop experience for patient care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.